Biodesix, Inc., announced that final results of the first completed biomarker-stratified, validation study in oncology will be presented at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31st – June 4th, 2013. ... read more

The Association of Clinical Research Organizations announced today it has joined the Coalition of Small Business Innovators (CSBI). CSBI is a national, non-partisan coalition of organizations dedicated to stimulating sustained, private investment in small, highly innovative companies focusing on the ... read more

The Biotechnology Industry Organization (BIO) announced today it has joined the Coalition of Small Business Innovators (CSBI). CSBI is a national, non-partisan coalition of organizations dedicated to stimulating sustained, private investment in small, highly innovative companies focused on the development of new technologies. ... read more

St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced the start of its landmark EnligHTNment clinical study. This is the largest randomized, prospective trial to determine whether renal denervation and medication offers additional health benefits beyond lowering blood pressure in patients with uncontrolled ... read more

Caligor Rx, a leader in the global procurement of comparator drugs for clinical trials worldwide, today announced that Managing Director Tammy Bishop has been elected to the Board of Directors for Diversity Alliance for Science (DA4S), a national organization that fosters supplier diversity within the life ... read more

Liquidia Technologies today announced that its collaborative agreement with PATH, a global health nonprofit organization, has been extended. The extension of this agreement allows for the continuation of preclinical proof-of-concept studies on a next generation pneumococcal vaccine. If successful, the vaccine could potentially allow for ... read more

OvaScienceSM, (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today the publication of an in-depth review article by Chief Scientific Officer, Scott Chappel, Ph.D., regarding the role of mitochondria ... read more

Medidata (NASDAQ: MDSO), the leading global provider of cloud-based solutions for the life sciences industry, today announced that Cory Douglas, chief financial officer, will present at the 14th Annual B. Riley & Co. Investor Conference on May 22, 2013, at 8:00 a.m. PT / 11:00 a.m. ... read more

Celerion is pleased to announce the appointment of Dr. Bruce Morimoto as Executive Director of Applied Translational Medicine. Dr. Morimoto will have responsibility for developing and implementing strategies for patient populations in early clinical research and clinical pharmacology studies. Dr. ... read more

KineMed Inc. (www.kinemed.com) today announced an agreement with MedImmune, the global biologics research and development arm of AstraZeneca, to study how a monoclonal antibody affects the dynamics of the cellular prion protein (PrPc). Cellular prion protein is found in ... read more

GlaxoSmithKline plc (GSK) today announced the launch of Discovery Fast Track, a competition designed to accelerate the translation of academic research into novel therapies. Winners of the competition will partner with investigators on GSK’s Discovery Partnerships with Academia (DPAc) team with a goal of developing ... read more

Kineta, Inc., a biotechnology company focused on the development of novel immune-modulating drugs for critical disease areas, and Hydra, LLC, today announced the completion of a major investment to add funding to Kineta’s clinical-stage drug programs. The investment is directed at Kineta’s two lead drug programs ... read more

InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today announced that an interview with InVivo Chief Executive Officer Frank Reynolds is scheduled to be aired on WBUR in Boston this morning during ... read more

Xellia Pharmaceuticals (“Xellia”), a pharmaceutical group focusing on the development, manufacturing and global commercialization of anti-infective therapies, announced today that Novo A/S (“Novo”), the holding company of the Novo Group, has purchased all shares of the group for approximately US$ 700 million from 3i and other ... read more

West Virginia University Hospitals (WVUH) wanted to acquire new technology to improve workflow and patient care in its busy radiology department. Using the Aquilion™ ONE ViSION Edition from Toshiba America Medical Systems, Inc., WVUH has expanded its existing imaging programs for a wide range of patient ... read more

Cordis Corporation, a global leader in innovative technology for cardiovascular interventions, will introduce the two latest additions to its portfolio of cardiovascular solutions at EuroPCR 2013, 21-24 May in Paris. EuroPCR is Europe’s largest meeting for interventional cardiovascular medicine. ... read more

Multiple targets, highly effective, breakthrough therapy for ALS sufferers may now be within reach. Winston Ko, the CEO of Genervon Biopharmaceuticals, will be presenting on Friday at the Neurotech Conference in San Francisco that its endogenous regulatory drug GM604 modulates over 80 ALS related gene targets ... read more

Pfizer Inc. announced today the discontinuation of a Phase 3 randomized, open-label, two-arm study (B1931008) evaluating the safety and efficacy of the investigational compound inotuzumab ozogamicin in patients with relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma (NHL) who are not candidates for intensive high-dose chemotherapy. In ... read more

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), today announced that it has commenced an underwritten public offering of 6,000,000 shares of its common stock. All of the shares in the offering are to be sold by NPS. J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC ... read more

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that its Board of Directors has established a Compliance Committee composed of three independent directors to provide oversight for all activities of the Company related to the U.S. Food and Drug Administration (FDA) warning letter for the Hayward site ... read more